Relief Therapeutics H1 Loss Narrows Despite Revenue Decline

Relief Therapeutics (RLF.SW) reported a H1 2025 net loss of CHF 4.5 million, a marginal improvement, despite revenues sharply declining to CHF 1.2 million from CHF 5.6 million in H1 2024, primarily due to the absence of non-recurring licensing income and a business model transition. This revenue drop widened the EBITDA loss to CHF 3.7 million. The company, holding CHF 12.5 million in cash providing an operational runway into late 2026, continues to advance key pipeline programs and pursue a strategic business combination with NeuroX, aiming to expand into digital neurotherapeutics.

Analysis

Relief Therapeutics (RLF.SW) reported a mixed financial performance for the first half of 2025, characterized by a marginal improvement in its bottom line but a significant deterioration in operational metrics and revenue. The net loss narrowed slightly to CHF 4.5 million from CHF 4.6 million year-over-year, with loss per share improving to CHF 0.357. However, this was overshadowed by a sharp revenue collapse to CHF 1.2 million, down from CHF 5.6 million in H1 2024. This decline is attributed to the absence of CHF 1.7 million in non-recurring licensing income and a strategic shift of its GOLIKE business to a partnership model. Consequently, the EBITDA loss widened to CHF 3.7 million from CHF 2.5 million, and the operating loss grew to CHF 4.4 million, indicating that cost management did not offset the revenue shortfall. Critically, the company maintains a cash position of CHF 12.5 million, which it states provides an operational runway into late 2026, a crucial factor for a development-stage firm. The forward-looking strategy is heavily reliant on advancing its clinical pipeline, including candidates RLF-TD011 and RLF-OD032, and executing a proposed business combination with NeuroX to pivot into digital neurotherapeutics.

Key Decisions for Investors

• Investors should weigh the security of the stated cash runway through late 2026 against the significant operational challenges highlighted by the sharp revenue decline and widening EBITDA loss.
• The company's valuation is now almost entirely dependent on future catalysts, so investment decisions should be based on an assessment of the clinical potential of its pipeline and the strategic merit of the proposed NeuroX combination.
• Monitor for any announcements regarding the GOLIKE partnership's performance and progress on the NeuroX transaction, as these are key to validating the company's strategic pivot and future revenue model.